Literature DB >> 8599864

Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells.

A J McIlwrath1, V G Brunton, R Brown.   

Abstract

We have analysed the cell-cycle arrests and cytotoxicity of the A2780 human ovarian cell line in response to geldanamycin, a benzoquinoid ansamycin that can inhibit tyrosine kinases. Geldanamycin causes a dose-dependent G2 arrest and reversible inhibition of entry into the S phase in A2780 cells. After a 3-h exposure to 0.1 microM geldanamycin, the cells show an increase in accumulation of p53 protein that is maximal at 24 h after drug exposure. Increased p53 levels can be induced in cells by DNA-damaging agents; however, using alkaline elution and sister chromatid exchange assays we detect no DNA damage induced by geldanamycin. Using dominant negative mutant TP53 transfectants of A2780 we have analysed the possible dependence of geldanamycin-induced cell-cycle arrests on the presence of functional p53. We observe no difference in cell-cycle arrests in mutant p53 transfectants known to have the p53-DNA damage-response pathway inactivated as compared with vector-alone controls. Similarly, we observe no difference in clonogenic resistance to the cytotoxicity of geldanamycin in these cells. These results suggest that geldanamycin can induce increased p53 protein by a mechanism not involving DNA damage. Furthermore, the cell-cycle arrests and cytotoxic effects of geldanamycin in these cells are not mediated by p53-dependent pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599864     DOI: 10.1007/s002800050407

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

2.  Mitogenesis by v-Src: a need for active oncoprotein both in leaving G0 and in completing G1 phases of the cell cycle.

Authors:  A W Wyke; W Cushley; J A Wyke
Journal:  Cell Growth Differ       Date:  1993-08

3.  Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity.

Authors:  A J McIlwrath; P A Vasey; G M Ross; R Brown
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

4.  Effect of herbimycin A on growth and pp60c-src activity in human colon tumor cell lines.

Authors:  R Garcia; N U Parikh; H Saya; G E Gallick
Journal:  Oncogene       Date:  1991-11       Impact factor: 9.867

5.  Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.

Authors:  L R Kelland; P Mistry; G Abel; S Y Loh; C F O'Neill; B A Murrer; K R Harrap
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

6.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Authors:  B C Behrens; T C Hamilton; H Masuda; K R Grotzinger; J Whang-Peng; K G Louie; T Knutsen; W M McKoy; R C Young; R F Ozols
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

7.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase.

Authors:  Y Uehara; M Hori; T Takeuchi; H Umezawa
Journal:  Jpn J Cancer Res       Date:  1985-08

9.  Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin group.

Authors:  H Yamaki; H Suzuki; E C Choi; N Tanaka
Journal:  J Antibiot (Tokyo)       Date:  1982-07       Impact factor: 2.649

10.  Growth inhibition by anchorage-deficiency is associated with increased level but reduced phosphorylation of mutant p53.

Authors:  K Takahashi; K Suzuki; Y Uehara; T Ono
Journal:  Jpn J Cancer Res       Date:  1992-04
View more
  6 in total

Review 1.  Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Authors:  H J Ochel; K Eichhorn; G Gademann
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

2.  Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis.

Authors:  Lisa Pham; Lisa Christadore; Scott Schaus; Eric D Kolaczyk
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-25       Impact factor: 11.205

3.  In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.

Authors:  Nan Zheng; Peng Zou; Shaomeng Wang; Duxin Sun
Journal:  Drug Metab Dispos       Date:  2010-12-22       Impact factor: 3.922

4.  Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Authors:  Ruben A Mesa; David Loegering; Heather L Powell; Karen Flatten; Sonnet J H Arlander; Nga T Dai; Michael P Heldebrant; Benjamin T Vroman; B Douglas Smith; Judith E Karp; Cynthia J Ten Eyck; Charles Erlichman; Scott H Kaufmann; Larry M Karnitz
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

5.  Identification of p53 Activators in a Human Microarray Compendium.

Authors:  J Christopher Corton; Kristine L Witt; Carole L Yauk
Journal:  Chem Res Toxicol       Date:  2019-09-03       Impact factor: 3.973

Review 6.  Protein tyrosine phosphatases in glioma biology.

Authors:  Anna C Navis; Monique van den Eijnden; Jan T G Schepens; Rob Hooft van Huijsduijnen; Pieter Wesseling; Wiljan J A J Hendriks
Journal:  Acta Neuropathol       Date:  2009-11-21       Impact factor: 17.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.